Trends for Market Access, HEOR, and Real World Evidence
This blog reviews trends for using health economics and outcomes research and real-world evidence to…
Certara2019年5月10日
Real World Evidence Marches Forward in Drug Development
The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…
Certara2019年3月20日
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…
Jieun Choe2018年6月2日
Drug Asset Evaluation: Increasing “Probability of Success” of a Deal
Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…
Danielle Pillsbury2017年8月24日
Model-based Meta-analysis: An Innovative Methodology Comes of Age
MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…
Danielle Pillsbury2016年7月14日
Short-term Efficacy Reliably Predicts Long-term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-based Meta-analysis
The objective of this study was to assess the relationship between short-term and long-term treatment…
Danielle Pillsbury2016年7月1日
Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis
Gastric emptying (GE) is often reported to be slower and more irregular in premature neonates than…
Danielle Pillsbury2015年5月1日
A Model-based Dose-response Meta-analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma
PURPOSE: To characterize dose and response for intraocular pressure (IOP) reduction and incidence of hyperemia…
Danielle Pillsbury2015年5月1日
Time Course of Bone Mineral Density Changes with Denosumab Compared with Other Drugs in Postmenopausal Osteoporosis: A Dose-response-based Meta-analysis
Our objective was to compare the time course of bone mineral density (BMD) changes at…
Danielle Pillsbury2014年10月1日
